Reference – Research Projects

Current Research Projects at MMI

The Nuclear Medicine and PET division of Macquarie Medical Imaging is currently engaged in several research projects with local and international research groups. They cover the fields of: neurology, cardiology, oncology and respiratory research. MMI is a pro-active partner with Macquarie University (MU) and Macquarie University Hospital (MUH) in winning major international research projects, playing pivotal roles in the tendering process.

International Research at MMI:

  1. Parkinson’s Progression Markers Initiative. MUH and MMI were chosen as the only Australian location for this 5 year research project. Our role is to image candidates several times over a five year period. Using a PET/CT hybrid camera, PET/MRI fusion software, and innovative dopamine imaging radio-pharmaceuticals (PPMI F18AV-133) we are able to scan a candidate’s brain and detect Parkinson’s at an early stage. We then track the rate of dopamine decline with subsequent PET/CT/MRI scans over the five year period. Our partners are: The institute for Neurodegenerative Disorders; MUH Neurology department; and The Michael J Fox Foundation.
  2. LZAX and LZAO; Amaloid Imaging in patients with Alzheimer’s Disease. This project will commence in the near future. On site testing of equipment and the building of imaging protocols has been completed. We are awaiting our first candidates for imaging using innovative amaloid imaging radio-pharmaceuticals (F18 AV 45).
    Our partners are: Molecular Neuroimaging L.L.C ; MUH Neurology department; Avid Radio-pharmaceuticals.
  3. PLATO Prostate Cancer (MDV3100-10). A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
  4. PROSPER Prostate Cancer (MDV3100-14). A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
  5. METRIC Breast Cancer (CDX011-04) A randomised Multicentre Privotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
  6. Tau Imaging PET- Effect of Passive Immunization on the progression of Mild Alzheimer’s Disease. PET/CT scan using F18-AV-1451. Molecular Neuroimaging L.L.C ; MUH Neurology department; Avid Radio-pharmaceuticals.
  7. UPTAKE Prostate Cancer (9785-CL-0403) A multicentre, single-arm, open-label, post-marketing safety study to evaluate the risk of seizure among subjects with metastatic castration-resistant prostate cancer (mCRPC) treated with Enzalutamide who are at potential increased risk of seizure

Local Research at MMI:

  • Airway Closure of Asthmatics and treatment of airways on imaging using SPECT/CT
    Asthmatics have their lungs scanned using an inhaled radio-pharmaceutical called Tc99m/Technigas. Subsequent scans are also taken after the candidate is given an antagonist to induce mild asthma symptoms. These 2 scans are them repeated once the candidate has undergone several weeks of therapy. We are using SPECT/CT imaging to quantify the candidate’s initial airways capability in a normal situation and when they suffer mild asthma symptoms. We also repeat this series of scans after the candidate has several weeks of treatment for comparison.
  • Our Partner is:

    Woolcock Institute of Medical Research.